Form 4: Inozyme Pharma Director Reports Option Disposition Following BioMarin Merger Completion

Inozyme Pharma Director Lynne Sullivan reported the disposition of stock options as Inozyme Pharma, Inc. completed its merger with BioMarin Pharmaceutical Inc. at $4.00 per share, resulting in cash payouts for eligible options.

Summary

• Lynne Marie Sullivan, a Director of Inozyme Pharma, Inc., reported the disposition of stock options.
• The disposition occurred as a result of the Agreement and Plan of Merger, dated May 16, 2025, by and among Inozyme Pharma, Inc., BioMarin Pharmaceutical Inc. ("Parent"), and Incline Merger Sub, Inc. ("Merger Sub").
• Merger Sub completed a cash tender offer to acquire all outstanding common stock of Inozyme Pharma, Inc. for $4.00 per share.
• Effective July 1, 2025, Merger Sub merged with and into Inozyme Pharma, Inc., with Inozyme Pharma, Inc. continuing as the surviving corporation and as a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Outstanding stock options with an exercise price less than the $4.00 merger consideration were automatically accelerated, fully vested, cancelled, and converted into a cash payment equal to the difference between the merger consideration and the option's exercise price.
• Lynne Sullivan's stock option to buy 28,368 shares at an exercise price of $2.77 was disposed of, resulting in a cash payment of $1.23 per share ($4.00 $2.77).

Sentiment

Score: 7

Explanation: The sentiment is positive for option holders and shareholders who received cash for their holdings, indicating a successful exit via acquisition. However, it marks the end of Inozyme Pharma as an independent entity, which could be seen as neutral or slightly negative for those who preferred its standalone growth.

Positives

• Stock options with an exercise price below the merger consideration were automatically accelerated and fully vested.
• Option holders received a cash payment for the intrinsic value of their options.
• The merger provides liquidity and a defined exit for Inozyme Pharma shareholders and option holders.

Negatives

• Inozyme Pharma, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Shareholders and option holders no longer participate in the future upside potential of Inozyme Pharma as a standalone company.

Future Outlook

The document primarily reports a past transaction (merger completion and related option disposition) and does not provide forward-looking statements or guidance for the now acquired entity.

Industry Context

This transaction reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger companies like BioMarin acquire smaller, often clinical-stage, firms like Inozyme Pharma to expand their pipelines or acquire specific assets. Such mergers provide an exit strategy for investors in smaller companies and can offer synergies for the acquiring entity.

Stakeholder Impact

• Shareholders: Received $4.00 per share in cash, providing liquidity and a defined return on investment.
• Option Holders: Received cash for their in-the-money options, with acceleration and vesting.
• Employees: Inozyme Pharma employees are now part of BioMarin Pharmaceutical Inc., subject to integration plans.
• Customers/Suppliers: Operations of Inozyme Pharma will continue under BioMarin, potentially leading to changes in relationships or processes.

Next Steps

• Inozyme Pharma, Inc. will operate as a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• The reporting person, Lynne Sullivan, is no longer subject to Section 16 reporting obligations for Inozyme Pharma, Inc. as a public company.

Key Dates

Recommendation

Keywords

Inozyme Pharma, INZY, BioMarin Pharmaceutical, Merger, Acquisition, SEC Form 4, Stock Options, Tender Offer, Corporate Action, Biotechnology, Pharmaceuticals